LISCure Biosciences, a Seoul, South Korea-based biotech company that researches and develops bacteria-mediated immunotherapy, raised $5m in seed funding.
Backers included NHN Investment, Shinhan Investment, and KB Securities.
The company intends to use the funds to strengthen its research and development capabilities of key technologies.
Established in December 2018, LISCure is currently developing a “bacteria-mediated immunotherapy” that can be used to treat people by itself or in combination with other drugs. It is for major indications such as tumors, degenerative neurological diseases, autoimmune diseases, metabolic diseases, etc. The company currently has seven pipelines of medicine and two pipelines of health-functioning food and is considering the introduction of two more pipes.